Aug 2026· EBioMedicine· Vol 131, pp. 106437· 0 citations· 44 references
Medicine
TL;DR
Disease progression in SCA27B is characterised by mild progression, ageing-related motor variabilities and comorbidities, and associated with repeat size on both alleles, and associated with repeat size on both alleles.
Abstract
Summary Background Spinocerebellar Ataxia 27B (SCA27B) is a novel, frequent and likely treatable late-onset autosomal-dominant ataxia caused by GAA repeat-expansions in FGF14. For understanding disease evolution and imminent trial planning, metrics of the most widely used clinical outcome assessment (Scale for the Assessment and Rating of Ataxia/SARA), longitudinal progression and modifiers thereof are warranted. Methods Multicentre intercontinental observational study (2015–2024) of 661 assessments from 219 patients with SCA27B (age: 68 ± 10 years; SARA: 9 ± 6 points) with item-level distribution-based analyses to characterise SARA metrics relative to ageing-related impairment in 390 healthy controls; and linear mixed-effects modelling to determine longitudinal progression and demographic or genetic modifiers. Findings Ataxia severity in SCA27B as assessed by SARA was primarily attributable to gait, stance, and lower-limb impairment; other ataxia domains scored ≤1 SARA point in 79–94% of patients. Discrimination of SCA27B motor performance from controls decreased with age due to ageing-related motor variability captured by SARA, thus limiting potential metric response windows for symptomatic treatments. Disease progression was faster in the presence of interfering ageing-related comorbidities in 14 (6%) patients. Overall longitudinal progression of SCA27B was 0.54 SARA points/year [95% CI: 0.37–0.71]. Expansions of (GAA)> 180 repeats were frequent also on the shorter allele (n = 18 (8%), range: 196–348 repeats), and associated with faster progression (+1.6 SARA points/year, [95% CI: 0.9–2.2]), including also otherwise less affected ataxia domains speech and sitting. Interpretation Disease progression in SCA27B is characterised by mild progression, ageing-related motor variabilities and comorbidities, and associated with repeat size on both alleles. Funding Else-Kröner-Fresenius-Stiftung, EU, DFG, BMBF, CIHR, NAF, Ataxia-UK, CSC.
It is argued that stage-specific, multimodal composites, integrated through harmonized international cohorts and machine learning, offer the most credible path to prognostic enrichment and to shorter, adequately powered, and preventive trials.
Ying-Zi Hao, Xian-Jun Hao· Frontiers in Neurology· 0 citations
Although AT subtypes differ substantially in childhood and adolescence, neurological decline converges to a similar pace in adulthood, irrespective of subtype or genotype, which inform counselling, prognostication, and the design of interventional trials, including mutation-specific therapies.
A. Hensiek, L. Bottolo, M. Tiet et al.· Brain : a journal of neurolo...· 0 citations
The clinimetric properties of the Patient-Reported Outcome Measure of Ataxia (PROM-Ataxia) have only been partially explored. This study aimed to investigate its convergent validity, responsiveness, and minimal clinically important difference (MCID), as well as its discriminative ability at the earliest disease stages...
K. Leeuwenberg, T. V. van Prooije, C. Reniers et al.· Journal of Neurology· 0 citations
The genetics, epidemiology, clinical spectrum, imaging findings, differential diagnosis, and management of SCA27B are reviewed, and routine FGF14 testing in patients with unexplained late-onset ataxia, downbeat nystagmus, or episodic cerebellar symptoms is supported.
Anish Mehta, Sharvani Gowtham, I. S. M. Giridhar et al.· Annals of Movement Disorders· 0 citations
UBTF-related CONDBA presents with early normal or mildly delayed development followed by regression and progressive ataxia, and elevated NFL may serve as a biomarker of neuronal injury in both humans and animal models.
A. Nagy, A. Luddy, Francine Molay et al.· Journal of Medical Genetics· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.